Table 1 Clinical characteristics of the study group in relation to platelet reactivity, expressed as quartiles of serum thromboxane B 2 concentration
Clinical parameters | TXB2 | TXB2 | TXB2 | TXB2 | p |
|---|---|---|---|---|---|
<50 pg/mL | [50-150 pg/mL) | [150-450 pg/mL) | ≥450 pg/mL | ||
n = 45 | n = 49 | n = 47 | n = 45 | ||
Age [years] | 69.2 (±8.8) | 70.0 (±7.4) | 66.7 (±8.7) | 64.7 (±9.3) | 0.0062 |
Female gender [n (%)] | 27 (60.0%) | 24 (49.0%) | 20 (42.6%) | 23 (51.1%) | 0.32 |
Duration of diabetes [years] | 5 (2-10) | 6 (3-10) | 6 (3-11) | 5 (2-7) | 0.36 |
Anthropometric parameters | |||||
BMI [kg/m2] | 29.1 (±4.3) | 29.4 (±4.4) | 31.2 (±5.4) | 31.8 (±5.3) | 0.005 |
SBP [mmHg] | 142.6 (±19.4) | 141.3 (±18.8) | 135.3 (±16.7) | 141.9 (±19.3) | 0.64 |
DBP [mmHg] | 79.3 (±9.5) | 80.9 (±12.1) | 79.8 (±10.7) | 81.0 (±13.4) | 0.56 |
Diabetes treatment [n (%)] | Â | Â | Â | Â | Â |
Metformin | 29 (64.4%) | 24 (49.0%) | 35 (74.5%) | 36 (80.0%) | 0.0188 |
Sulfonylurea derivatives | 30 (66.7%) | 40 (81.6%) | 35 (74.5%) | 22 (48.9%) | 0.0485 |
Sulfonylurea derivatives and metformin | 15 (33.3%) | 18 (36.7%) | 25 (53.2%) | 14 (31.1%) | 0.74 |
Acarbose | 2 (4.4%) | 5 (10.2%) | 7 (14.9%) | 5 (11.1%) | 0.22 |
DPP-4 inhibitors, TZD and glinides | 0 | 0 | 0 | 0 | - |
Coexisting conditions [n (%)] | |||||
Hypertension | 42 (93.3%) | 45 (91.8%) | 41 (87.2%) | 42 (93.3%) | 0.80 |
Dyslipidaemia | 37 (82.2%) | 45 (91.8%) | 40 (85.1%) | 35 (77.8%) | 0.39 |
CAD | 19 (42.2%) | 31 (63.3%) | 22 (46.8%) | 26 (57.8%) | 0.39 |
Previous MI | 9 (20.0%) | 16 (32.7%) | 14 (29.8%) | 10 (22.2%) | 0.91 |
Chronic HF | 12 (26.7%) | 21 (42.9%) | 15 (31.9%) | 18 (40.0%) | 0.38 |
- NYHA class I | 1 (2.2%) | 6 (12.3%) | 2 (4.3%) | 5 (11.1%) | 0.23 |
- NYHA class II | 8 (17.8%) | 9 (18.4%) | 10 (21.3%) | 11 (24.4%) | |
- NYHA class III | 3 (6.7%) | 6 (12.3%) | 3 (6.4%) | 2 (4.4%) | |
- NYHA class IV | 0 | 0 | 0 | 0 | |
Previous stroke or TIA | 5 (11.1%) | 5 (10.2%) | 4 (8.5%) | 2 (4.4%) | 0.24 |
Current smoking | 3 (6.7%) | 3 (6.1%) | 6 (12.8%) | 6 (13.3%) | 0.16 |
Treatment of concomitant diseases [n (%)] | |||||
β-blocker | 33 (73.3%) | 29 (59.2%) | 32 (68.1%) | 32 (71.1%) | 0.96 |
- carvedilol or nebivolol | 4 (8.9%) | 6 (12.3%) | 4 (8.5%) | 1 (2.2%) | 0.16 |
ACE-I or ARB | 36 (80.0%) | 39 (79.6%) | 37 (78.7%) | 34 (75.6%) | 0.60 |
Aldosterone antagonist | 1 (2.2%) | 5 (10.2%) | 6 (12.8%) | 4 (8.9%) | 0.23 |
Other diuretics | 25 (55.6%) | 21 (42.9%) | 26 (55.3%) | 21 (46.7%) | 0.97 |
CCB | 18 (40.0%) | 11 (22.5%) | 18 (38.3%) | 23 (51.1%) | 0.13 |
Statin | 34 (75.6%) | 40 (81.6%) | 34 (72.3%) | 31 (68.9%) | 0.27 |